rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    EXEL
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Exelixis at UBS conference: zanzalintinib sets up next growth phase
      Nov 17Investing.comEXELUBS
      Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything | The Motley Fool

      Exelixis’ leading pipeline candidate is inching closer to approval.

      Nov 16The Motley FoolEXEL
      Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch. | The Motley Fool

      These catalysts could impact growth down the road.

      Nov 13The Motley FoolEXEL
      Forget clinical cash burns: Why Exelixis is up 38% since June
      Nov 12Investing.comEXEL
      Exelixis Nears FDA Decision, Key Kidney Cancer Data for Zanzalintinib
      Nov 11Yahoo FinanceEXEL
      Exelixis Inc stock hits all-time high at 73.49 USD
      Nov 5Investing.comEXEL
      Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
      Nov 3Yahoo FinanceEXEL
      Top 3 Health Care Stocks That May Fall Off A Cliff This Quarter
      Nov 2BenzingaEXELREGN
      Exelixis (EXEL) International Revenue in Focus: Trends and Expectations
      Nov 2Yahoo FinanceEXEL
      Earnings Beat Could Be A Game Changer For Exelixis Stock (EXEL)
      Oct 31Yahoo FinanceEXEL
      Exelixis (EXEL) Beats Q3 Estimates, Is The Stock Fully Priced?
      Oct 31Yahoo FinanceEXEL
      EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales
      Oct 30Yahoo FinanceEXEL
      Exelixis Inc (EXEL) (Q3 2026) Earnings Call Highlights: CABOMETYX Momentum and Zanzalintinib ...
      Oct 30Yahoo FinanceEXEL
      BMO raises Exelixis stock price target to $60 on OpEx outlook
      Oct 30Investing.comEXEL
      What Exelixis (EXEL) Said on Its Q3 Earnings Call
      Oct 30Yahoo FinanceEXEL
      Exelixis Q3 2026 slides: CABOMETYX growth funds zanzalintinib push
      Oct 29Investing.comEXEL
      Exelixis Q3 2026 Earnings Call Transcript
      Oct 29BenzingaEXEL
      Earnings call transcript: Exelixis tops Q3 2026 estimates as stock slips
      Oct 29Investing.comEXEL
      Exelixis beats Q3 estimates but stock edges lower on guidance
      Oct 29Investing.comEXEL
      Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
      Oct 29Yahoo FinanceEXEL
      Exelixis earnings beat by $0.07, revenue topped estimates
      Oct 29Investing.comEXEL
      Exelixis (EXEL) Surpasses Q3 Earnings and Revenue Estimates
      Oct 29Yahoo FinanceEXEL
      Exelixis: Q3 Earnings Snapshot
      Oct 29Yahoo FinanceEXEL
      Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
      Oct 29Yahoo FinanceEXEL
      Exelixis (EXEL) vs. BMRN and NBIX: Can CABOMETYX and Pipeline Growth Revive Investor Confidence?
      Oct 29Yahoo FinanceEXEL
      Exelixis earnings loom: Can Cabometyx offset zanzalintinib delay?
      Oct 29Investing.comEXEL
      Exelixis stock hits all-time high at 65.62 USD
      Oct 28Investing.comEXEL
      Exelixis Rises with Earnings on Tap
      Oct 23Yahoo FinanceEXEL
      Exelixis (EXEL) Stock May Be A Bargain Despite Its 223% Run
      Oct 23Yahoo FinanceEXEL
      Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
      Oct 22Yahoo FinanceEXEL
      Exelixis Inc stock hits all-time high at 63.39 USD
      Oct 20Investing.comEXEL
      Citizens raises Exelixis stock price target to $65 on ESMO data
      Oct 19Investing.comEXEL
      Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
      Oct 15Yahoo FinanceEXEL
      Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
      Oct 15Yahoo FinanceEXEL
      Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
      Oct 13MorningstarEXEL
      Exelixis Inc stock hits all-time high at 61.21 USD
      Oct 12Investing.comEXEL
      Bank of America Securities Sticks to Its Sell Rating for Exelixis (EXEL)

      Tipranks Press Release.

      Oct 10The Globe and MailEXEL
      RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating

      Exelixis (EXEL) has an average rating of overweight and mean price target of $54.87, according to an

      Oct 9Yahoo FinanceEXEL
      RBC Trims Price Target on Exelixis to $45 From $46, Keeps Sector Perform Rating
      Oct 8Yahoo FinanceEXEL
      Is Exelixis (EXEL) Fully Valued As Its Cabozantinib Patent Window Comes Into Focus?
      Oct 8Yahoo FinanceEXEL
      Is Exelixis Stock Engineered To Make You Money?
      Oct 7Yahoo FinanceEXEL
      Exelixis Shares Rising on CABOMETYX Revenue

      Big Money pushes Exelixis, Inc. (EXEL) shares higher by 149% since 2017.

      Sep 30Yahoo FinanceEXEL
      Exelixis stock hits all-time high at 59.73 USD
      Sep 30Investing.comEXEL
      Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?

      Exelixis faces a three-month FDA review delay for zanzalintinib, pushing the potential CRC decision to March 2027.

      Sep 24Yahoo FinanceEXEL
      Exelixis (EXEL) Gets FDA Review Extension For Zanzalintinib განაცხად tometastatic Colorectal Cancer

      Exelixis (NasdaqGS: EXEL) said the FDA has extended its review of zanzalintinib plus atezolizumab for metastatic colorectal cancer. The agency lengthened the decision timeline after Exelixis submitted a major amendment with updated safety and efficacy data. The extended FDA review tied to new zanzalintinib safety and efficacy information only captures part of what matters today. Check out 4 other big wins that Exelixis investors should know about. To put this regulatory update in context,...

      Sep 21Yahoo FinanceEXEL
      Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B

      Exelixis (NASDAQ:EXEL) President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises through internal development, selective business development and potential collaborations, while preparing for a planned launch of zanzalintinib in metastatic colorectal cancer

      Sep 17Yahoo FinanceEXEL
      Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?

      Exelixis, Inc. (NASDAQ:EXEL) disclosed in a September 11 filing that the FDA had extended the review of zanzalintinib by three months, setting a new target action date of March 3, 2027. The September 10 notification followed an FDA request for updated safety and efficacy information. The submitted data were classified as a major amendment. The […]

      Sep 17Yahoo FinanceEXEL
      Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle

      Exelixis (NASDAQ:EXEL) executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza, in colorectal cancer later this year. Speaking at a Wells biotech session, Chief Financial Officer Chris Senner said the company is worki

      Sep 15Yahoo FinanceEXEL
      Citizens reiterates Exelixis stock rating on FDA review extension
      Sep 14Investing.comEXEL
      Exelixis: Why The 3-Month Delay Is More Negative Than It May Seem (Downgrade)
      Sep 14Seeking AlphaEXEL

      This is the newest page. Registered accounts read further back.